LEO Targets Peplin for Skin Cancer Drug
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 9 (Table of Contents)
Published: 15 Sep-2009
DOI: 10.3833/pdr.v2009.i9.1244 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Denmark’s LEO Pharma, a global leader within dermatology and critical care agreed to acquire the Australian company, Peplin, for US$287...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS